Global Hairy Cell Leukaemia Market - Segmented by Therapy and Geography - Growth, Trends and Forecast (2018 - 2023)

  • ID: 4591258
  • Report
  • Region: Global
  • 110 pages
  • Mordor Intelligence
UP TO OFF
until Dec 31st 2018
1 of 5

FEATURED COMPANIES

  • Abbvie
  • Astellas Pharma
  • Astrazeneca
  • Biogenomics Limited
  • Juno Therapeutics
  • Medimmune
  • MORE
The hairy cell leukaemia market is expected to register a CAGR of 5% during the forecast period 2018 to 2023. Hairy cell leukaemia is a type of blood cancer associated with accumulation of abnormal lymphocytes.

Increase in Diagnosis Rates

Hairy cell leukaemia is a very rare type of cancer, which accounts for approximately 2% of leukaemia’s. Hairy cell leukaemia is characterized by the uncontrolled accumulation of lymphocytes by bone marrow, overproducing them. Early diagnosis can help the patients live longer. In recent years, there are advanced diagnostic tests to detect the hairy cell leukaemia. First and foremost diagnostic test is a complete blood profile which clearly indicates the total number of lymphocytes, which indicates the disease. Physicians can easily diagnose, if there is an enlarged spleen, by physical examination. One important confirmation test is presence of hairy cells in the blood in the lab tests. Finally, most of the patients require bone marrow biopsy for confirmation. Most of the patients who receive treatment can be disease-free for at least 10 years. Diagnosis rate of hairy cell leukaemia is increased during last two-three decades, which drives the market. The other factors which drives the market is growing geriatric population

Lack of Awareness of Symptoms Due to Insignificant Research Studies

Hairy cell leukaemia is very infrequent type of leukaemia, which is rarely known to the people all over the world. There is no proper data available on incidence or prevalence of hairy cell leukaemia, which implies an insufficient research documents. This disease can be treated if diagnosed in early stages, but due to lack of awareness of the symptoms of hairy cell leukaemia among people limits the diagnosis of the disease, which is a major factor restricting the growth of the market. The other factors, such as limited health services in rural hospitals, is the major restraint for the global hairy cell leukaemia market.

North America Lead the Market

The hairy cell leukaemia market holds the largest market share in North America Region for the year 2017 due to the presence of high incidence rate, increase in ageing population and advancements in the treatment of hairy cell leukaemia which is followed by Europe

Major Players: ABBVIE, ASTELLAS PHARMA, ASTRAZENECA, BIOGENOMICS LIMITED, F. HOFFMANN-LA ROCHE AG, INCYTE CORP., JUNO THERAPEUTICS, MEDIMMUNE, AND NOVARTIS, among others.

Reasons to Purchase this Report
  • Current and future hairy cell leukaemia market outlook in the developed and emerging markets
  • Analyzing various perspectives of the market with the help of Porter’s five forces analysis
  • The segment that is expected to dominate the market
  • Regions that are expected to witness fastest growth during the forecast period
  • Identify the latest developments, market shares, and strategies employed by the major market players
  • 3 months analyst support along with the Market Estimate sheet (in excel)
Customization of the Report

This report can be customized to meet your requirements.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abbvie
  • Astellas Pharma
  • Astrazeneca
  • Biogenomics Limited
  • Juno Therapeutics
  • Medimmune
  • MORE
1. Introduction
1.1 Market Definition

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview
5.1 Current Market Scenario
5.2 Porter's Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry within the Industry

6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Increase in Diagnosis Rates
6.1.2 Growing Geriatric Population
6.2 Market Restraints
6.2.1 Lack of Awareness of the Symptoms Due to Insignificant Research Studies
6.2.2 Limited Health Services in Rural Hospitals
6.3 Opportunities
6.4 Key Challenges

7. Market Segmentation
7.1 By Therapy
7.1.1 Chemotherapy
7.1.1.1 Cladribine
7.1.1.2 Pentostatin
7.1.1.3 Others
7.2 Segmentation - by Geography
7.2.1 North America
7.2.1.1 United States
7.2.1.2 Canada
7.2.1.3 Mexico
7.2.2 Europe
7.2.2.1 France
7.2.2.2 Germany
7.2.2.3 United Kingdom
7.2.2.4 Italy
7.2.2.5 Spain
7.2.2.6 Rest of Europe
7.2.3 Asia-Pacific
7.2.3.1 China
7.2.3.2 Japan
7.2.3.3 India
7.2.3.4 Australia
7.2.3.5 New Zealand
7.2.3.6 South Korea
7.2.3.7 Rest of Asia-Pacific
7.2.4 Middle East & Africa
7.2.4.1 GCC
7.2.4.2 South Africa
7.2.4.3 Rest of Middle East & Africa
7.2.5 South America
7.2.5.1 Brazil
7.2.5.2 Argentina
7.2.5.3 Rest of South America

8. Competitive Landscape
8.1 Mergers and Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Product Launches

9. Key Players
9.1 AbbVie
9.2 Astellas Pharma
9.3 AstraZeneca
9.4 Biogenomics Limited
9.5 F. Hoffmann-La Roche AG
9.6 Incyte Corp.
9.7 Juno Therapeutics
9.8 MedImmune
9.9 Novartis
9.10 Others

10. Future of the Market
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Abbvie
  • Astellas Pharma
  • Astrazeneca
  • Biogenomics Limited
  • F. Hoffmann-La Roche Ag Incyte Corp.
  • Juno Therapeutics
  • Medimmune
  • Novartis
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll